Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00668382
Other study ID # UM200702
Secondary ID
Status Completed
Phase Phase 1
First received April 25, 2008
Last updated May 10, 2013
Start date July 2007
Est. completion date July 2011

Study information

Verified date May 2013
Source University of Massachusetts, Worcester
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.


Description:

Intratumoral injection of alpha gal glycolipid in experimental knockout mouse model systems incorporates into tumor cell membranes and presents these xeno-transplantation epitopes to antigen presenting cells with that particular tumor's tumor associated antigens (TAA). Thus this maneuver converts any individual tumor into an in situ tumor vaccine without the need to isolate, purify or supply TAA exogenously. The effects in these model systems demonstrate both the upregulation of cytotoxic T cells which react against the particular tumor's TAA, as well as resolution of injected primary tumor and eradication and prevention of metastatic disease at distant sites. This current study was undertaken to investigate the safety and feasibility of such an approach in humans. The major toxicity concerns are acute allergic or complement activation reactions or development of autoimmunity. The primary treatment is a single intratumoral injection of alpha gal glycolipid. The study design is a standard dose escalation design and the primary endpoint is Dose limiting toxicity at one month after injection (grade 3 or 4. Subjects are followed until death utilizing standard clinical imaging and evaluation to judge overall tumor response.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Patients with solid tumors who have failed standard therapies, or are not candidates for standard therapies.

2. Patients must have at least one measurable lesion that is accessible and suitable for injection of the GSL alpha-GAL.

3. Patients should not be undergoing any active treatment with chemotherapy, radiotherapy, or steroids (either because the patient or the treating physician have decided not to employ these therapies at this time, or because they had already been tried and failed). If they have been treated with these modalities, the treatments should have been completed at least two weeks prior to date of injection of GSL alpha-GAL.

4. Patients should be judged by the investigator to be able to undergo safely the procedure needed to inject the tumor with GSL alpha-GAL.

5. Age equal or over 18 years old.

6. ECOG (Eastern Cooperative Oncology Group ) performance of less than 2. (International Normalized Ratio) INR less than 1.5 and a (Partial Thromboplastin Time) PTT no greater than normal limits within 1 week prior to intra-tumoral injection (For patients who requires invasive procedure for intra-tumoral injection).

7. Laboratory Criteria (completed equal or less 2 weeks before enrollment) Hematologic: (White Blood Cell Count) WBC equal or above 3500/millimeter-cubed or (Absolute Neutrophil Count) ANC equal or above 1500/millimeter-cubed and platelet count equal or above 100,000/ millimeter-cubed.

Hepatic: Total bilirubin equal or less 4.0 milligrams/deciliter. Renal: Creatinine equal or less 2.2 milligrams/deciliter.

8. Patients must be negative for HIV (circulating antibody), Hepatitis B (circulating antigen), and Hepatitis C (circulating antibody).

9. Patients should have an expected survival of more than 6 weeks and should not have other systemic anti-tumor treatments planned during this time frame.

Exclusion Criteria:

1. Patients who are pregnant (as determined by a positive serum HCG (Human Chorionic Gonadotropin) in patients of childbearing potential) or nursing.

2. Patients under the age of 18.

3. Patients with severe infections or septicemia.

4. Patients with a history of autoimmune disease.

5. Patients in, or about to be in, active treatment with chemotherapy or steroids.

6. Patients who refuse HIV/hepatitis testing and patients who do not sign an approved consent form.

7. Patient has received other investigational drugs within 14 days before enrollment or is expected to participate in an experimental drug study during this study treatment.

8. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Biological:
Alpha-Gal Glycosphingolipid
Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity

Locations

Country Name City State
United States University of Massachusetts Medical School Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
University of Massachusetts, Worcester

Country where clinical trial is conducted

United States, 

References & Publications (4)

DiGiacomo A, North RJ. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J Exp Med. 1986 Oct 1;164(4):1179-92. Erratum in: J Exp Med 1986 — View Citation

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15;174(12):7516-23. — View Citation

Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother. 2004 Oct;53(10):879-92. Epub 2004 Jul 28. Review. — View Citation

Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999 Nov 15;163(10):5211-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Greater Than Grade 3 or 4 Toxicity Grade 3/4 Toxicity occurring in a participant within a month of intratumoral injection 1 month Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02953756 - Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
Terminated NCT02565433 - Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302) N/A
Completed NCT00184353 - Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T. N/A
Recruiting NCT02789371 - Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions N/A
Completed NCT01122199 - Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors Phase 1
Terminated NCT01336985 - Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads Phase 1
Recruiting NCT05419518 - Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas Phase 2
Completed NCT02808416 - Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) Phase 1
Completed NCT00152906 - Stereotactic Radiotherapy (SRT) Liver (COLD 1) Phase 1/Phase 2
Completed NCT01267084 - A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1/Phase 2
Recruiting NCT02327065 - Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion N/A
Completed NCT02382653 - Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain N/A
Completed NCT01273480 - A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1
Completed NCT01273493 - A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction Phase 1
Completed NCT00556049 - Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT02246634 - Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) N/A
Terminated NCT01970644 - Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases N/A